Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Evolution of MRD Testing in Colorectal Cancer

April 1st 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Dr Li on the Utility of ADG126 Plus Pembrolizumab in MSS CRC

March 29th 2024

Daneng Li, MD, discusses the implications of a study evaluating ADG126 in combination with pembrolizumab in patients with MSS colorectal cancer.

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Considerations for Platinum-based Therapy

March 28th 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Practical Considerations in MRD Testing in CRC

March 25th 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Colorectal Cancer: MRD Testing in the Community Setting

March 25th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

FDA Green Lights Fluorouracil Safety Label Update Regarding Use in Patients With DPD Deficiency

March 21st 2024

The FDA has approved safety label changes for fluorouracil products to include information regarding the agent’s use in patients with DPD.

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

March 21st 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.

Testing for MRD in Colorectal Cancer

March 18th 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

MRD Testing Platforms in Colorectal Cancer

March 18th 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

QOL Remains a Key Goal of the Use of Radiation in Rectal Cancer

March 14th 2024

Nina Sanford, MD, discusses how radiation could help improve QOL for patients with rectal cancer and situations when radiation or surgery could be omitted.

Consideration for Fruquintinib Dosing and Titration

March 14th 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

March 14th 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Multitargeted DNA Test Bests Fecal Immunochemical Test With Higher Sensitivity for CRC

March 13th 2024

Higher sensitivity for CRC and advanced precancerous lesions, but lower specificity for advanced neoplasia, was seen with a next-generation stool DNA test vs a fecal immunochemical test.

Q-TWiST Analysis Demonstrates Benefit of Fruquintinib Plus BSC in Pretreated mCRC

March 12th 2024

Sebastien Stintzing, MD, discusses a Q-TWiST analysis for fruquintinib vs placebo in pretreated metastatic colorectal cancer.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

When is MRD Testing Performed in Colorectal Cancer Treatment?

March 11th 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

March 11th 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.